After evaluating and applying this model (Supplementary Fig. 3), we obtained predicted drug-target interactions, including for potentially novel E3 ligases, such as Makorin Ring Finger Protein 1 (MKRN1), having PPIs with key tumor drivers, TP53 and APC32, and predicted to interact with DB13955 (Estradiol dienanthate) and DB03017 (Lauric acid). Here, TP53 is linked to neoplasm.